DiaSorin SpA (DIAS)

149.60
+4.20(+2.89%)
  • Volume:
    242,852
  • Bid/Ask:
    149.50/149.60
  • Day's Range:
    147.10 - 150.15

DIAS Overview

Prev. Close
145.4
Day's Range
147.1-150.15
Revenue
881.31M
Open
147.5
52 wk Range
133.3-207.6
EPS
-
Volume
242,852
Market Cap
8.19B
Dividend (Yield)
1.00
(0.69%)
Average Vol. (3m)
231,725
P/E Ratio
-
Beta
-0.07
1-Year Change
-10.42%
Shares Outstanding
54,722,145
Next Earnings Date
Jul 30, 2021
What is your sentiment on DiaSorin SpA?
or
Market is currently closed. Voting is open during market hours.

DiaSorin SpA News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuyBuy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyNeutral

DiaSorin SpA Company Profile

DiaSorin SpA Company Profile

Employees
2066
Market
Italy

DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.

Read More
  • Che successe, mentre il resto sale?
    0
    • Overrated company, in my opinion you can sell Short Diasorin capitalization 11 billion euros Profits 175 million euros Turnover 800 million ISIN IT0003492391 diasorin
      6
      • short!!
        6
        • alla faccia del fattoquotidiano che oggi ha provato a dare un'altra spallata a questo gioiello... Coronavirus: da Fda via libera a test sierologico DiaSorin L'autorizzazione per analisi validata al San Matteo di Pavia (ANSA) - ROMA, 25 APR - DiaSorin annuncia di aver ricevuto l'Emergency Use Authorization (EUA) dalla Food and Drug Administration americana per il test LIAISON  SARS-CoV-2 S1/S2 IgG. Si tratta del nuovo test sierologico validato presso il Policlinico San Matteo a Pavia, uno dei centri di riferimento nazionali per la pandemia da COVID-19.
          3
          • DIASORIN COVID fast test has been approved by FDA
            0
            • nice news, not sure why is going down anyway
              0
            • When??????
              0
          • USA: Dow e NASDAQ han chiuso a +10%. Lunedì si parte da 120.10€. Buon weekend
            1
            • E invece... 109.90€ :D
              0
          • DiaSorin’s test could be ready within six weeks for consideration by the U.S. Food and Drug Administration, and the QIAGEN test could be ready within 12 weeks for FDA consideration, according to HHS.
            0
            • They just announced a fast test for COVID-19, 60 minutes against some hours
              0
              • 150€ during this year ?
                1
                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.